Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash from Financing Activities data on record, last reported at $2.9 million in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $2.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $111.4 million, a 8.0% increase, with the full-year FY2025 number at $108.5 million, up 4.82% from a year prior.
  • Cash from Financing Activities reached $2.9 million in Q1 2026 per IKT's latest filing, down from $108.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for IKT hit a ceiling of $108.6 million in Q4 2025 and a floor of -$204769.0 in Q1 2022.
  • A 5-year average of $17.2 million and a median of $181954.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 259834.29% in 2024, then tumbled 173.72% in 2025.
  • Tracing IKT's Cash from Financing Activities over 5 years: stood at -$204769.0 in 2022, then skyrocketed by 32.56% to -$138104.0 in 2023, then surged by 72280.72% to $99.7 million in 2024, then rose by 8.91% to $108.6 million in 2025, then tumbled by 97.33% to $2.9 million in 2026.
  • Business Quant data shows Cash from Financing Activities for IKT at $2.9 million in Q1 2026, $108.6 million in Q4 2025, and -$134130.0 in Q3 2025.